FDA Grants Orphan Drug Status to Aldoxorubicin
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted multiple Orphan Drug Designations for the Company's lead drug candidate, aldoxorubicin.